Two for Two on The Analytical Scientist's Power List

Two for Two on The Analytical Scientist's Power List

August 21, 2014

Two from ASTech (Trajan's collaboration with UTAS and ARC) have graced The Analytical Scientist's Power Lists for two consecutive years:

  • 2013 and 2014 - Emily Hilder, ASTech Training Centre Director; Professor and Head of Discipline, Chemistry, Australian Centre for Research on Separation Science (ACROSS), School of Physical Sciences, UTAS.
  • 2014 - Michael Breadmore, ASTech Steering Committee Member; Professor and ARC Future Fellow, Australian Centre for Research on Separation Science (ACROSS), School of Physical Science, UTAS.

This could be you! Boost your postgraduate career at ASTech. Apply now.

Read more at The Analytical Scientist:




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More